Boehringer Ingelheim enters global licensing agreement to develop and commercialise antibodies from… EP News Bureau Jun 3, 2022 This partnership allows Boehringer Ingelheim to strengthen its tumour cell-directed Antibody-Drug Conjugate (ADC) and immune…
